Read by QxMD icon Read

NAFLD fibrosis score

R Jin, A Krasinskas, N-A Le, J V Konomi, J Holzberg, R Romero, M B Vos
BACKGROUND: Plasminogen activator inhibitor-1 (PAI-1) is the primary inhibitor of the endogenous fibrinolytic system and is known to be increased in obesity, insulin resistance and non-alcoholic fatty liver disease (NAFLD). We previously demonstrated that PAI-1 levels were closely related to the amount of hepatic steatosis in children. OBJECTIVES: The aim of this study was to characterize plasma PAI-1 in relationship to severity of inflammation and fibrosis, as well as to plasma lipids in children with NAFLD...
October 20, 2016: Pediatric Obesity
Kojiro Seki, Toshihide Shima, Hirohisa Oya, Yasuhide Mitsumoto, Masayuki Mizuno, Takeshi Okanoue
AIM: Transient elastography (TE) is a noninvasive method for predicting liver fibrosis. However, there is limited data regarding the performance of TE in Japanese patients with nonalcoholic fatty liver disease (NAFLD). We aimed to evaluate the association between liver stiffness measurement (LSM) by TE and liver fibrosis stage, and define a cut-off value for predicting liver fibrosis. METHODS: A total of 171 Japanese patients with biopsy-proven NAFLD underwent LSM using TE with FibroScan®...
October 18, 2016: Hepatology Research: the Official Journal of the Japan Society of Hepatology
Sunil V Pawar, Vinay G Zanwar, Ajay S Choksey, Ashok R Mohite, Samit S Jain, Ravindra G Surude, Qais Q Contractor, Pravin M Rathi, Ravi U Verma, Premlata K Varthakavi
:  Background and rationale. Nonalcoholic fatty liver disease (NAFLD) is the most common cause of pediatric liver disease in western countries. Its prevalence in Indian subcontinent is not well studied. MATERIAL AND METHODS: In a school based cross sectional study we have screened overweight and obese children in the age group of 11 to 15 years for NAFLD. Ultrasonography, elevated serum transaminases, fibroscan were used for defining NAFLD. Dietary habits, blood pressure, serum lipid profile, blood counts and insulin resistance were recorded...
November 2016: Annals of Hepatology
Erina Kumagai, Yohei Mano, Sachiyo Yoshio, Hirotaka Shoji, Masaya Sugiyama, Masaaki Korenaga, Tsuyoshi Ishida, Taeang Arai, Norio Itokawa, Masanori Atsukawa, Hideyuki Hyogo, Kazuaki Chayama, Tomohiko Ohashi, Kiyoaki Ito, Masashi Yoneda, Takumi Kawaguchi, Takuji Torimura, Yuichi Nozaki, Sumio Watanabe, Masashi Mizokami, Tatsuya Kanto
Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic non-viral liver disease. YKL-40, chitinase-like protein expressed in multiple tissues including liver, is involved in cell proliferation, inflammation and remodeling of the extracellular matrix. The aim of this study was to assess whether serum YKL-40 levels are associated with liver fibrosis in NAFLD patients. Serum YKL-40 levels were quantified in 111 NAFLD patients and 23 HCC patients with NAFLD. To identify the source of YKL-40, immunofluorescence staining of liver specimens from NAFLD patients was performed...
October 14, 2016: Scientific Reports
Stuart McPherson, Tim Hardy, Jean-Francois Dufour, Salvatore Petta, Manuel Romero-Gomez, Mike Allison, Claudia P Oliveira, Sven Francque, Luc Van Gaal, Jörn M Schattenberg, Dina Tiniakos, Alastair Burt, Elisabetta Bugianesi, Vlad Ratziu, Christopher P Day, Quentin M Anstee
OBJECTIVES: Non-invasive fibrosis scores are widely used to identify/exclude advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). However, these scores were principally developed and validated in patients aged between 35 and 65 years of age. The objective of this study was to assess the effect of age on the performance of non-invasive fibrosis tests in NAFLD. METHODS: Patients were recruited from European specialist hepatology clinics. The cohort was divided into five age-based groups: ≤35 (n=74), 36-45 (n=96), 46-55 (n=197), 56-64 (n=191), and ≥65 years (n=76), and the performance of the aspartate aminotransferase (AST)/alanine transaminase (ALT) ratio, fibrosis 4 (FIB-4), and NAFLD fibrosis score (NFS) for advanced fibrosis (stage F3-F4) for each group was assessed using liver biopsy as the standard...
October 11, 2016: American Journal of Gastroenterology
Martin L Decaris, Kelvin W Li, Claire L Emson, Michelle Gatmaitan, Shanshan Liu, Yenny Wang, Edna Nyangau, Marc Colangelo, Thomas E Angel, Carine Beysen, Jeffrey Cui, Carolyn Hernandez, Len Lazaro, David A Brenner, Scott M Turner, Marc K Hellerstein, Rohit Loomba
: Excess collagen synthesis (fibrogenesis) in the liver plays a causal role in the progression of nonalcoholic fatty liver disease (NAFLD). Methods are needed to identify patients with more rapidly progressing disease and to demonstrate early response to treatment. We describe here a novel method to quantify hepatic fibrogenesis flux rates both directly in liver tissue and non-invasively in blood. Twenty-one patients with suspected NAFLD ingested heavy water ((2) H2 O, 50 ml aliquots) 2-3 times daily for 3 to 5 weeks prior to a clinically indicated liver-biopsy...
October 5, 2016: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
Carmen Fierbinteanu-Braticevici, Crina Sinescu, Alexandru Moldoveanu, Ana Petrisor, Sorina Diaconu, Dragos Cretoiu, Bogdan Braticevici
Nonalcoholic fatty liver disease (NAFLD) is very prevalent and now considered the most common cause of chronic liver disease. Staging the severity of liver damage is very important because the prognosis of NAFLD is highly variable. The long-term prognosis of patients with NAFLD remains incompletely elucidated. Even though the annual fibrosis progression rate is significantly higher in patients with nonalcoholic hepatitis (NASH), both types of NAFLD (nonalcoholic fatty liver and nonalcoholic steatohepatitis) can lead to fibrosis...
September 28, 2016: Cell Biology and Toxicology
Serena Pelusi, Salvatore Petta, Chiara Rosso, Vittorio Borroni, Anna Ludovica Fracanzani, Paola Dongiovanni, Antonio Craxi, Elisabetta Bugianesi, Silvia Fargion, Luca Valenti
BACKGROUND: The clinical determinants of fibrosis progression in nonalcoholic fatty liver disease (NAFLD) are still under definition. AIM: To assess the clinical determinants of fibrosis progression rate (FPR) in NAFLD patients with baseline and follow-up histological evaluation, with a special focus on the impact of pharmacological therapy. METHODS: In an observational cohort of 118 Italian patients from tertiary referral centers, liver histology was evaluated according to Kleiner...
2016: PloS One
Hind I Fallatah, Hisham O Akbar, Alyaa M Fallatah
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is being increasingly recognized as a cause of chronic liver disease. It has also been associated with devastating outcomes such as decompensated liver cirrhosis and hepatocellular carcinoma, as well as diabetes and metabolic syndrome. OBJECTIVES: This study was conducted in order to assess liver fibrosis using Fibroscan, and to compare these results to the use of Fibrosis-4 (FIB-4) scores, AST platelet ratio index (APRI scores), and the AST/ALT ratios on NAFLD patients...
July 2016: Hepatitis Monthly
Salvatore Petta, Vincent Wai-Sun Wong, Calogero Cammà, Jean-Baptiste Hiriart, Grace Lai-Hung Wong, Fabio Marra, Julien Vergniol, Anthony Wing-Hung Chan, Vito Di Marco, Wassil Merrouche, Henry Lik-Yuen Chan, Marco Barbara, Brigitte Le-Bail, Umberto Arena, Antonio Craxì, Victor de Ledinghen
BACKGROUND AND AIMS: Liver stiffness measurement (LSM) frequently overestimates the severity of liver fibrosis In Nonalcoholic Fatty Liver Disease (NAFLD). Controlled Attenuation Parameter (CAP) is a new parameter provided by the same machine used for LSM, and associated with both steatosis and BMI, the two factors mostly affecting LSM peformance in NAFLD. We aimed to determine wheter prediction of liver fibrosis by LSM in NAFLD patients is affected by CAP values. METHODS: Patients (n=324) were assessed by clinical and histological (Kleiner score) features...
September 17, 2016: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
Claudio Tana, Marco Tana, Stefano Rossi, Mauro Silingardi, Cosima Schiavone
PURPOSE OF THE STUDY: Conventional ultrasound (US) is reliable to reveal the presence of non-alcoholic fatty liver disease (NAFLD), but it is neither sensitive nor specific to reveal fibrosis clues, except in advanced stages where signs of cirrhosis are evident. NALFD fibrosis score is a non-invasive parameter that predicts well the presence of significant fibrosis, but correlations with US parameters are lacking. The aim of this study was, therefore, to compare resistive index of hepatic artery (HARI) of NAFLD patients with different severity degrees of diffuse fatty liver disease vs HARI of controls, and to compare HARI of NAFLD patients with different NAFLD fibrosis scores vs HARI of controls...
September 2016: Journal of Ultrasound
María José Morlán-Coarasa, María Teresa Arias-Loste, Víctor Ortiz-García de la Foz, Obdulia Martínez-García, Carmen Alonso-Martín, Javier Crespo, Manuel Romero-Gómez, Emilio Fábrega, Benedicto Crespo-Facorro
RATIONALE: Patients with schizophrenia spectrum disorders have increased morbidity and mortality, largely due to cardiovascular disease, which is associated with antipsychotic treatment. OBJECTIVES: Because of the link between cardiometabolic risk, non-alcoholic fatty liver disease (NAFLD), and antipsychotics, we aimed to investigate the development of NAFLD during the first 3 years of antipsychotic treatment in first episode non-affective psychosis patients. RESULTS: A sample of 191 subjects was included in final analyses, randomly assigned to aripiprazole (N = 83), risperidone (N = 12), quetiapine (N = 46), and ziprasidone (N = 50)...
September 12, 2016: Psychopharmacology
Hannes Hagström, Patrik Nasr, Mattias Ekstedt, Stergios Kechagias, Per Stål, Pierre Bedossa, Rolf Hultcrantz
BACKGROUND AND AIMS: A new score for the histological severity of nonalcoholic fatty liver disease (NAFLD), called SAF (Steatosis, Activity and Fibrosis) has been developed. We aimed to evaluate the impact of this score on overall mortality. METHODS: We used data from 139 patients with biopsy-proven NAFLD. All biopsies were graded according to the SAF scoring system and disease severity was classified as mild, moderate or severe. Causes of death were extracted from a national, population-based register...
September 10, 2016: Scandinavian Journal of Gastroenterology
Andrew M Shearer, Rajashree Rana, Karyn Austin, James D Baleja, Nga Nguyen, Andrew Bohm, Lidija Covic, Athan Kuliopulos
Chronic liver inflammation and fibrosis in NASH can lead to cirrhosis and liver failure for which there are currently no approved treatments. Protease Activated Receptor-2 (PAR2) is an emerging new target expressed on liver stellate cells and hepatocytes that regulates the response to liver injury and inflammation. Here, we identified a pepducin to block the deleterious actions of PAR2 in promoting liver fibrosis. Non-alcoholic fatty liver disease (NAFLD) and early fibrosis was induced by the methionine-choline deficient diet (MCD) in mice...
September 9, 2016: Journal of Biological Chemistry
Zhuo Wu, Zi-Liang Cheng, Zhi-Long Yi, Ming-Wei Xie, Hong Zeng, Lie-Jing Lu, Xiao Xu, Jun Shen
PURPOSE: To evaluate the usefulness of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in the assessment of nonalcoholic fatty liver disease (NAFLD) severity. MATERIALS AND METHODS: Liver DCE-MRI at 3.0T was performed in 36 adult Sprague-Dawley rats with methionine choline-deficient diet-induced NAFLD and 10 untreated control rats. Pharmacokinetic parameters of DCE-MRI including K(trans) , Kep , Ve , Vp , and hepatic portal index (HPoI) were measured using the dual-input extended Tofts model...
September 8, 2016: Journal of Magnetic Resonance Imaging: JMRI
Janki Patel, Ricki Bettencourt, Jeffrey Cui, Joanie Salotti, Jonathan Hooker, Archana Bhatt, Carolyn Hernandez, Phirum Nguyen, Hamed Aryafar, Mark Valasek, William Haufe, Catherine Hooker, Lisa Richards, Claude B Sirlin, Rohit Loomba
BACKGROUND: Magnetic resonance imaging-estimated proton-density-fat-fraction (MRI-PDFF) has been shown to be a noninvasive, accurate and reproducible imaging-based biomarker for assessing steatosis and treatment response in nonalcoholic steatohepatitis (NASH) clinical trials. However, there are no data on the magnitude of MRI-PDFF reduction corresponding to histologic response in the setting of a NASH clinical trial. The aim of this study was to quantitatively compare the magnitude of MRI-PDFF reduction between histologic responders versus histologic nonresponders in NASH patients...
September 2016: Therapeutic Advances in Gastroenterology
Raxitkumar Jinjuvadia, Fadi Antaki, Prateek Lohia, Suthat Liangpunsakul
BACKGROUND: Prevalence of nonalcoholic fatty liver disease (NAFLD) and rate of advanced fibrosis among individuals with metabolic syndrome (MetS) and its individual metabolic abnormalities needs better understanding in the United States population. We aim to study these by using a large United States population database, the Third National Health and Nutrition Examination Survey (NHANES III). METHODS: A total of 11,674 individuals were included in our study cohort...
August 31, 2016: Journal of Clinical Gastroenterology
Jeffrey B Schwimmer, Joel E Lavine, Laura A Wilson, Brent A Neuschwander-Tetri, Stavra A Xanthakos, Rohit Kohli, Sarah E Barlow, Miriam B Vos, Saul J Karpen, Jean P Molleston, Peter F Whitington, Philip Rosenthal, Ajay K Jain, Karen F Murray, Elizabeth M Brunt, David E Kleiner, Mark L Van Natta, Jeanne M Clark, James Tonascia, Edward Doo
BACKGROUND & AIMS: No treatment for nonalcoholic fatty liver disease (NAFLD) has been approved by regulatory agencies. We performed a randomized controlled trial to determine whether 52 weeks of cysteamine bitartrate delayed release (CBDR) reduces the severity of liver disease in children with NAFLD. METHODS: We performed a double-masked trial of 169 children with NAFLD Activity Scores ≥ 4 at 10 centers. From June 2012 to January 2014, the patients were randomly assigned to receive CBDR or placebo twice daily (300 mg for ≤65 kg, 375 mg for >65-80 kg, 450 mg for >80 kg) for 52 weeks...
August 25, 2016: Gastroenterology
Hamid Kalantari, Farhad Moradi, Akbar Hassanzade
BACKGROUND: Liver biopsy is required to diagnose non-alcoholic steatohepatitis in patients with suspected non-alcoholic fatty liver disease (NAFLD). This study aimed to examine the relationship between sonographic diagnosis of fatty liver with histopathologic abnormalities and liver biopsy findings in patient with NAFLD. MATERIALS AND METHODS: In this cross-sectional study, a total of 180 patients, with an age range of 18-60 year old, with NAFLD based on ultrasonograghic findings were evaluated...
2016: Advanced Biomedical Research
M Munteanu, D Tiniakos, Q Anstee, F Charlotte, G Marchesini, E Bugianesi, M Trauner, M Romero Gomez, C Oliveira, C Day, J-F Dufour, S Bellentani, Y Ngo, S Traussnig, H Perazzo, O Deckmyn, P Bedossa, V Ratziu, T Poynard
BACKGROUND: Blood tests of liver injury are less well validated in non-alcoholic fatty liver disease (NAFLD) than in patients with chronic viral hepatitis. AIMS: To improve the validation of three blood tests used in NAFLD patients, FibroTest for fibrosis staging, SteatoTest for steatosis grading and ActiTest for inflammation activity grading. METHODS: We pre-included new NAFLD patients with biopsy and blood tests from a single-centre cohort (FibroFrance) and from the multicentre FLIP consortium...
October 2016: Alimentary Pharmacology & Therapeutics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"